Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ENDO HEALTH SOLUTIONS INC. | d355106d8k.htm |
 Endo Pharmaceuticals Holdings Inc.
2012 Annual Stockholders Meeting
May 23, 2012
1
Exhibit 99.1
©2012 Endo Pharmaceuticals Inc. All rights reserved.
|
 ©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved.
2
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements including
words such as “believes,” “expects,”
“anticipates,”
“intends,”
“estimates,”
“plan,”
“will,”
“may,”
“look forward,”
“intend,”
“guidance,”
“future”
or similar expressions are forward-looking statements. Because these
statements reflect our current views, expectations and beliefs concerning
future events, these forward-looking statements involve risks and
uncertainties. Investors should note that many factors, as more fully
described under the caption “Risk Factors”
in our Form 10-K, Form 10-Q and Form 8-K filings with the
Securities and Exchange Commission and as otherwise enumerated herein or therein,
could affect our future financial results and could cause our actual results
to differ materially from those expressed in forward-looking statements
contained in our Annual Report on Form 10-K. The forward-looking
statements in this presentation are qualified by these risk factors. These are factors
that, individually or in the aggregate, could cause our actual results to differ
materially from expected and historical results. We assume no obligation to
publicly update any forward-looking statements, whether as a result of
new information, future developments or otherwise. |
 Solutions for 21
st
Century Healthcare
I.
Our Diversified Business
II.
2012 Growth Drivers
III.
Commitment to Innovation
IV.
2012 Financial Guidance
V.
Summary
3
©2012 Endo Pharmaceuticals Inc. All rights reserved.
|
 Endo…
A vision for healthcare
total Lidoderm prescriptions written
combined years in healthcare industry
for executive leadership team
Conducts business in more than
Total
4,477
©2012 Endo Pharmaceuticals Inc. All rights reserved.
|
 Value
Creation in a Changing Healthcare Environment ©2012 Endo
Pharmaceuticals Inc. All rights reserved. |
 Solid
Track Record of Sales Growth Endo expects to report more than $3 Billion in
2012 sales 6
Sustaining our Growth
©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved. |
 Strong Cash Flow Generation
7
©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved. |
 Diversified Healthcare Solutions Company
8
*Pro forma -
Includes full year of AMS.
**The
services
segment
does
not
include
the
pro
forma
impact
of
pre-acquisition
revenues
from
the
recently
acquired
electronic
medical
records
providers,
Intuitive Medical Software (IMS) and meridian EMR, Inc.
©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved. |
 2012
Performance – Positioned for Strong Second Half
9
•
Anticipate strong second half 2012 driven by
revenue growth opportunities across all segments
•
Expect expense to revenue ratios to decrease
significantly from combination of revenue growth
and expense management
©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved. |
 Commitment to Innovation
10
Branded
Pharmaceuticals
Medical Devices
Generic
Pharmaceuticals
Generic Development
•
Continually enhancing
existing products
•
Recent advances:
—
AdVance™
XP
(OUS)
•
Developing treatments in
new areas
—
Topas™
sling
—
Cryotherapy
•
Exploring new emerging
technologies
•
Key Therapeutic Areas
•
Pain
•
Oncology
•
Endocrinology
•
Semi-Virtual R&D Model
•
Global Partnerships
•
Discovery
•
Early Development
•
Development Pipeline
Supplements strong
commercial base growth
AVEED™
(NDA)
Long Acting Injectable Testosterone
BEMA®
Buprenorphine
(Ph. III) Pain
Urocidin™
(Ph. III)
Bladder Cancer
Androgen Receptor Antagonist (Ph.
I) Castration Resistant Prostate Cancer
©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved. |
 2012
Guidance 11
Guidance
Revenue range
$3.15B -
$3.30B
Adjusted diluted EPS range
$5.00 -
$5.20
Reported (GAAP) diluted EPS range
$1.75 -
$1.95
©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved. |
 2012
Value Creation Opportunities 12
•
Successfully launch new formulation of OPANA ER
•
Support the future growth of Qualitest
o
Invest capital to capture growing demand for products
o
Exceed cost synergies assumed at time of Qualitest acquisition
•
Invest in AMS to accelerate growth
o
Scale successful AMS/Endo pilot programs
o
Invest in R&D to accelerate advance of new products to market
•
Maximize operating cash flow to pay down debt
o
Have completed ~$500M of cumulative debt repayments on our
existing Term Loan indebtedness
©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved. |
 13
*
*
*
*
*
*
*
©2012 Endo Pharmaceuticals Inc. All rights reserved.
|
 ©2012
Endo
Pharmaceuticals
Inc.
All
rights
reserved.
14
Reconciliation of Non-GAAP Measures
For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s
Current Report on Form 8-K filed today with the Securities and Exchange
Commission Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted
Diluted Earnings Per Share Guidance for the Year Ending December 31, 2012 Lower End of
Range Upper End of Range
Projected GAAP diluted income per common share
$1.75
$1.95
Upfront and milestone-related payments to partners
$0.71
$0.71
Amortization of commercial intangible assets and inventory step-up
$1.87
$1.87
Acquisition and integration costs related to recent acquisitions.
$0.29
$0.29
One-time payment now expected to be made to Impax Labs
$0.90
$0.90
Impairment of long-lived assets
$0.33
$0.33
Interest expense adjustment for ASC 470-20 and other treasury items
$0.21
$0.21
Tax effect of pre-tax adjustments at the applicable tax rates and certain other
expected cash tax savings as a result of recent acquisitions
($1.06)
($1.06)
Diluted adjusted income per common share guidance
$5.00
$5.20
The company's guidance is being issued based on certain assumptions including:
•Certain of the above amounts are based on estimates and there
can be no assurance that Endo will achieve these results
•Includes all completed business development transactions as of
May 23, 2012 |
 Endo Pharmaceuticals Holdings Inc.
2012 Annual Stockholders Meeting
May 23, 2012
15
©2012 Endo Pharmaceuticals Inc. All rights reserved.
|